Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases

Supplied by PerkinElmer on Wednesday, 07 September, 2022

Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.

Learn about key strategies and innovations in this space that are enabling advanced gene therapy.

Related White Papers

Monitoring secrets from North America’s largest healthcare services company

Learn about the cutting edge solutions McKesson implemented to optimise processes and deliver...

The solution for a seamless quantitative bioanalysis

High selectivity is a critical element of successful quantitative bioanalysis. Recent...

Advantages of Wavelength Scanning in Fluorescence and Absorbance Assays

EnVision® Multilabel Plate Reader, widely used in biological assay studies across the field...

  • All content Copyright © 2023 Westwick-Farrow Pty Ltd